Socazolimab not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “6\~8 cycles of Socazolimab (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w. Followed with Socazolimab (5 mg/kg), Q3w.”In the company’s words, NCT06459687 on ClinicalTrials.gov
- Tested for
- Cervical Cancer
- Main trialPhase 3
- “The goal of this clinical trial is to evaluate the efficacy and safety of Socazolimab combined with chemotherapy with or without bevacizumab as first-Line treatment in persistent, recurrent, or metastatic cervical cancer. The main question it aims to answer is: Does Socazolimab combined with chemotherapy with or without bevacizumab better benefit patients with persistent, recurrent, or metastatic cervical cancer as first-line treatment compared with placebo combined with chemotherapy with or without bevacizumab. Participants will be treated with Socazolimab/placebo + chemotherapy ±…”In the company’s words, NCT06459687 on ClinicalTrials.gov
Other drugs for Cervical Cancer
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- JSKN033Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase 3
- Bulumtatug fuvedotinMabwell · Phase 3
- SHR-A2102Hengrui · Phase 3
- SYS6002CSPC · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
Coming up1
- 1 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Sep 2027 | Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026